drugset
drugset / Trial / NCT05985161

A Study of Selinexor in People With Wilms Tumors and Other Solid Tumors

NCT05985161 ↗

Phase 2 Recruiting 45 enrolled Memorial Sloan Kettering Cancer Center
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to find out whether selinexor is an effective treatment for people who have a relapsed/refractory Wilms tumor, rhabdoid tumor, MPNST, BCOR-driven sarcoma, or another solid tumor that makes a higher than normal amount of XPO1 or has genetic changes that increase the activity of XP01.

Timeline

Start
2023-08-01
Primary completion
2029-08-01
Completion
2029-08-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Selinexor Other / unclassified 35 mg/m2 —

Indications

Wilms tumor malignant peripheral nerve sheath tumor rhabdoid tumor